PARIS (Reuters) – Valneva on Tuesday reported positive results for its COVID-19 vaccine in early stage clinical trials and said it planned to launch a Phase Three trial this month. The French drugmaker, whose shot uses the technology behind its licensed Japanese encephalitis vaccine, tested its vaccine in 153 adults with three dose levels based
Washington, D.C., officials are targeting next Monday for the start of phase two of reopening the nation’s capital after months of social restrictions due to the COVID-19 pandemic. Mayor Muriel Bowser said Wednesday that she would make a final decision and announcement on Friday. But if the numbers continue “trending in the right direction,” Bowser
A clinical trial testing the toxicity of a KRAS inhibitor demonstrated early promising antitumor activity and few adverse side effects in patients with advanced non-small cell lung cancer harboring KRAS G12C mutation, according to research presented today at the IASLC 2019 World Conference on Lung Cancer, hosted by the International Association for the Study of
A coeliac disease vaccine that aims to protect patients from the harmful effects of gluten has entered Phase 2 clinical trials in Melbourne. Following the commencement of global trials led by US-based pharmaceutical company ImmusanT Inc., the Australian trials will commence at the Royal Melbourne Hospital Clinical Trials Centre in Melbourne and then roll out
Writing in the June 1 issue of Cell Stem Cell, researchers at University of California San Diego School of Medicine report that a first-in-human phase I clinical trial in which neural stem cells were transplanted into participants with chronic spinal cord injuries produced measurable improvement in three of four subjects, with no serious adverse effects.